electroCore, Inc. (ECOR)
 NASDAQ: ECOR · Real-Time Price · USD
 4.880
 -0.160 (-3.17%)
  At close: Oct 30, 2025, 4:00 PM EDT
4.920
 +0.040 (0.82%)
  After-hours: Oct 30, 2025, 5:10 PM EDT
electroCore Revenue
electroCore had revenue of $7.38M in the quarter ending June 30, 2025, with 20.23% growth. This brings the company's revenue in the last twelve months to $27.70M, up 30.16% year-over-year. In the year 2024, electroCore had annual revenue of $25.18M with 57.09% growth.
Revenue (ttm) 
 $27.70M
Revenue Growth 
 +30.16%
P/S Ratio 
 1.50
Revenue / Employee 
 $379,452
Employees 
 73
Market Cap 
39.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 25.18M | 9.15M | 57.09% | 
| Dec 31, 2023 | 16.03M | 7.44M | 86.57% | 
| Dec 31, 2022 | 8.59M | 3.14M | 57.62% | 
| Dec 31, 2021 | 5.45M | 1.96M | 55.93% | 
| Dec 31, 2020 | 3.50M | 1.11M | 46.25% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
ECOR News
- 7 days ago - electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025 - GlobeNewsWire
- 27 days ago - electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms - GlobeNewsWire
- 4 weeks ago - electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium - GlobeNewsWire
- 5 weeks ago - electroCore's Truvaga™ Plus Named “Best Relaxation Gadget” in Esquire's 2025 Sleep Awards - GlobeNewsWire
- 7 weeks ago - Ecora Resources PLC (ECOR:CA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - electroCore Announces Departure of Peter Cuneo from the Board of Directors and Elects Thomas J. Errico, MD as Chairman of the Board - GlobeNewsWire
- 2 months ago - electroCore Partners with iHeartRadio and Former New York Jets Star Linebacker Greg Buttle to Champion Better Sleep and Stress Relief - GlobeNewsWire